PainChek Limited has appointed Sasha Grant as Head of Growth for its AI-powered Infant App, aiming to scale its presence in a $15 billion global market. Early Australian adoption shows promising conversion rates as the company prepares for international expansion.
- Sasha Grant appointed Head of Growth for PainChek Infant App
- Infant App targets $15 billion annual market of preverbal children
- App cleared by Australian and European regulators for infants 1-12 months
- Initial Australian downloads show 67% subscription conversion rate
- Plans underway for expansion into UK, Canada, Europe, and US markets
Strategic Leadership Boosts Infant App Ambitions
PainChek Limited (ASX, PCK), a pioneer in AI-driven pain assessment technology, has announced the appointment of Sasha Grant as Head of Growth for its PainChek Infant App. Grant brings a wealth of experience from leading consumer app growth initiatives, notably her role in scaling WikiCamps, Australia's top paid app with over 1.5 million users. Her expertise is expected to accelerate PainChek’s efforts to commercialize its innovative infant pain assessment tool globally.
A $15 Billion Market Opportunity
The PainChek Infant App addresses a significant unmet need, assessing pain in preverbal infants aged 1 to 12 months. With approximately 400 million preverbal children worldwide and 150 million babies born annually, the app’s total addressable market is estimated at around A$15 billion per year. The app uses smartphone cameras to analyze facial expressions and deliver a pain intensity score within three seconds, offering a quick, reliable tool for parents and healthcare professionals alike.
Early Adoption and Product Refinement
Since its launch on Apple and Google Play stores in Australia, the Infant App has recorded 261 downloads, with a strong 67% conversion rate from download to subscription. PainChek is actively refining the product experience, including redesigning the website, streamlining self-registration, and adjusting the free trial period to enhance user acquisition and retention. Partnerships, such as with CPR NSW Kids, are also helping to build trust and awareness among parents and healthcare providers.
Global Expansion on the Horizon
Looking ahead, PainChek plans to replicate the success of its Adult App by expanding the Infant App internationally. Target markets include the UK, Canada, and parts of Europe where regulatory clearances are already in place. The company is also preparing to engage with the US Food and Drug Administration to pursue regulatory approval stateside. Building healthcare professional endorsements and consumer advocacy will be critical to driving adoption in these new markets.
Balancing Promise with Execution
While the Infant App’s early traction is encouraging, revenue remains modest as the company focuses on optimizing its marketing funnel and product-market fit. The success of PainChek’s growth strategy will hinge on effective scaling, regulatory progress, and the ability to convert downloads into paying subscribers across diverse international markets.
Bottom Line?
PainChek’s appointment of a seasoned growth leader signals a pivotal phase in scaling its Infant App, with global market entry and revenue growth the next critical milestones.
Questions in the middle?
- How quickly can PainChek secure FDA clearance for the US market?
- Will the Infant App’s subscription model sustain growth amid competitive digital health tools?
- How effectively can PainChek leverage healthcare partnerships to drive adoption internationally?